drugset / Trial / NCT05425602
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.
Timeline
- Start
- 2022-07-31
- Primary completion
- 2023-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MAX-40279-01 | Unknown | 35 mg | — |
| Subject | MAX-40279-01 | Unknown | 50 mg | — |
| Subject | MAX-40279-01 | Unknown | 70 mg | — |
| Background | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | — |
Indications
No indication recorded.